Log in

Relevant bibliographies by topics / Marine drugs / Journal articles

Journal articles on the topic 'Marine drugs'

To see the other types of publications on this topic, follow the link: Marine drugs.

Author: Grafiati

Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Marine drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lu, Xiao-Ling, Qiang-Zhi Xu, Xiao-Yu Liu, Xin Cao, Kun-Yi Ni, and Bing-Hua Jiao. "Marine Drugs - Macrolactins." Chemistry & Biodiversity 5, no. 9 (September 24, 2008): 1669–74. http://dx.doi.org/10.1002/cbdv.200890155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gallo, Carmela, and Genoveffa Nuzzo. "Drugs from Marine Sources." Applied Sciences 11, no. 24 (December 20, 2021): 12115. http://dx.doi.org/10.3390/app112412115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Guan, Hua-Shi. "The Journal Marine Drugs and the First International Symposium on Marine Drugs (2004)." Marine Drugs 1, no. 1 (November 15, 2003): 3–4. http://dx.doi.org/10.3390/md101003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Farooqi, Ammad, Sundas Fayyaz, Ming-Feng Hou, Kun-Tzu Li, Jen-Yang Tang, and Hsueh-Wei Chang. "Reactive Oxygen Species and Autophagy Modulation in Non-Marine Drugs and Marine Drugs." Marine Drugs 12, no. 11 (November 13, 2014): 5408–24. http://dx.doi.org/10.3390/md12115408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Javed, Faraza, M. Imran Qadir, Khalid Hussain Janbaz, and Muhammad Ali. "Novel drugs from marine microorganisms." Critical Reviews in Microbiology 37, no. 3 (May 20, 2011): 245–49. http://dx.doi.org/10.3109/1040841x.2011.576234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shikov, Alexander N., Elena V. Flisyuk, Ekaterina D. Obluchinskaya, and Olga N. Pozharitskaya. "Pharmacokinetics of Marine-Derived Drugs." Marine Drugs 18, no. 11 (November 9, 2020): 557. http://dx.doi.org/10.3390/md18110557.

Full text

Abstract:

Marine organisms represent an excellent source of innovative compounds that have the potential for the development of new drugs. The pharmacokinetics of marine drugs has attracted increasing interest in recent decades due to its effective and potential contribution to the selection of rational dosage recommendations and the optimal use of the therapeutic arsenal. In general, pharmacokinetics studies how drugs change after administration via the processes of absorption, distribution, metabolism, and excretion (ADME). This review provides a summary of the pharmacokinetics studies of marine-derived active compounds, with a particular focus on their ADME. The pharmacokinetics of compounds derived from algae, crustaceans, sea cucumber, fungus, sea urchins, sponges, mollusks, tunicate, and bryozoan is discussed, and the pharmacokinetics data in human experiments are analyzed. In-depth characterization using pharmacokinetics is useful for obtaining information for understanding the molecular basis of pharmacological activity, for correct doses and treatment schemes selection, and for more effective drug application. Thus, an increase in pharmacokinetic research on marine-derived compounds is expected in the near future.

APA, Harvard, Vancouver, ISO, and other styles

7

Belarbi, E. "Producing drugs from marine sponges." Biotechnology Advances 21, no. 7 (October 2003): 585–98. http://dx.doi.org/10.1016/s0734-9750(03)00100-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Grosso, Clara, Patrícia Valentão, Federico Ferreres, and Paula Andrade. "Bioactive Marine Drugs and Marine Biomaterials for Brain Diseases." Marine Drugs 12, no. 5 (May 2, 2014): 2539–89. http://dx.doi.org/10.3390/md12052539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Russo, Patrizia, and Alfredo Cesario. "New Anticancer Drugs from Marine Cyanobacteria." Current Drug Targets 13, no. 8 (June 1, 2012): 1048–53. http://dx.doi.org/10.2174/138945012802009035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

De, Oindrila, and Biswa P. Chatterji. "Marine Derived Anticancer Drugs Targeting Microtubule." Recent Patents on Anti-Cancer Drug Discovery 12, no. 2 (June 5, 2017): 102–27. http://dx.doi.org/10.2174/1574892812666170109141003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Vignesh, S., A. Raja, and R. Arthur Jam. "Marine Drugs: Implication and Future Studies." International Journal of Pharmacology 7, no. 1 (December 15, 2010): 22–30. http://dx.doi.org/10.3923/ijp.2011.22.30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Simmons, T. Luke, Eric Andrianasolo, Kerry McPhail, Patricia Flatt, and William H. Gerwick. "Marine natural products as anticancer drugs." Molecular Cancer Therapeutics 4, no. 2 (February 1, 2005): 333–42. http://dx.doi.org/10.1158/1535-7163.333.4.2.

Full text

Abstract:

Abstract The chemical and biological diversity of the marine environment is immeasurable and therefore is an extraordinary resource for the discovery of new anticancer drugs. Recent technological and methodologic advances in structure elucidation, organic synthesis, and biological assay have resulted in the isolation and clinical evaluation of various novel anticancer agents. These compounds range in structural class from simple linear peptides, such as dolastatin 10, to complex macrocyclic polyethers, such as halichondrin B; equally as diverse are the molecular modes of action by which these molecules impart their biological activity. This review highlights several marine natural products and their synthetic derivatives that are currently undergoing clinical evaluation as anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

13

Lin, Shu-Kun, and Derek McPhee. "Marine Drugs -A New International Journal." Marine Drugs 1, no. 1 (November 15, 2003): 1–2. http://dx.doi.org/10.3390/md101001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Han, Ophelia. "Marine Drugs Best Paper Award 2013." Marine Drugs 11, no. 12 (February 26, 2013): 581–83. http://dx.doi.org/10.3390/md11030581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Mayer, Alejandro. "Marine Drugs Best Paper Award 2014." Marine Drugs 12, no. 2 (February 21, 2014): 1157–59. http://dx.doi.org/10.3390/md12021157.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Mayer, Alejandro. "Marine Drugs Best Paper Award 2015." Marine Drugs 13, no. 2 (February 16, 2015): 1068–70. http://dx.doi.org/10.3390/md13021068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Barbero, Héctor, Carlos Díez-Poza, and Asunción Barbero. "The Oxepane Motif in Marine Drugs." Marine Drugs 15, no. 11 (November 15, 2017): 361. http://dx.doi.org/10.3390/md15110361.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Dyshlovoy, Sergey A., and Friedemann Honecker. "Marine Drugs Acting as Autophagy Modulators." Marine Drugs 18, no. 1 (January 14, 2020): 53. http://dx.doi.org/10.3390/md18010053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sipkema, Detmer. "Marine biotechnology: diving deeper for drugs." Microbial Biotechnology 10, no. 1 (September 6, 2016): 7–8. http://dx.doi.org/10.1111/1751-7915.12410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Watters, Michael R. "Tropical Marine Neurotoxins: Venoms to Drugs." Seminars in Neurology 25, no. 03 (September 2005): 278–89. http://dx.doi.org/10.1055/s-2005-917664.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Haque, Neshatul, Sana Parveen, Tingting Tang, Jiaen Wei, and Zunnan Huang. "Marine Natural Products in Clinical Use." Marine Drugs 20, no. 8 (August 18, 2022): 528. http://dx.doi.org/10.3390/md20080528.

Full text

Abstract:

Marine natural products are potent and promising sources of drugs among other natural products of plant, animal, and microbial origin. To date, 20 drugs from marine sources are in clinical use. Most approved marine compounds are antineoplastic, but some are also used for chronic neuropathic pain, for heparin overdosage, as haptens and vaccine carriers, and for omega-3 fatty-acid supplementation in the diet. Marine drugs have diverse structural characteristics and mechanisms of action. A considerable increase in the number of marine drugs approved for clinical use has occurred in the past few decades, which may be attributed to increasing research on marine compounds in laboratories across the world. In the present manuscript, we comprehensively studied all marine drugs that have been successfully used in the clinic. Researchers and clinicians are hopeful to discover many more drugs, as a large number of marine natural compounds are being investigated in preclinical and clinical studies.

APA, Harvard, Vancouver, ISO, and other styles

22

Fernández-Peña, Laura, Carlos Díez-Poza, Paula González-Andrés, and Asunción Barbero. "The Tetrahydrofuran Motif in Polyketide Marine Drugs." Marine Drugs 20, no. 2 (February 3, 2022): 120. http://dx.doi.org/10.3390/md20020120.

Full text

Abstract:

Oxygen heterocycles are units that are abundant in a great number of marine natural products. Among them, marine polyketides containing tetrahydrofuran rings have attracted great attention within the scientific community due to their challenging structures and promising biological activities. An overview of the most important marine tetrahydrofuran polyketides, with a focused discussion on their isolation, structure determination, approaches to their total synthesis, and biological studies is provided.

APA, Harvard, Vancouver, ISO, and other styles

23

Sithranga Boopathy, N., and K. Kathiresan. "Anticancer Drugs from Marine Flora: An Overview." Journal of Oncology 2010 (2010): 1–18. http://dx.doi.org/10.1155/2010/214186.

Full text

Abstract:

Marine floras, such as bacteria, actinobacteria, cyanobacteria, fungi, microalgae, seaweeds, mangroves, and other halophytes are extremely important oceanic resources, constituting over 90% of the oceanic biomass. They are taxonomically diverse, largely productive, biologically active, and chemically unique offering a great scope for discovery of new anticancer drugs. The marine floras are rich in medicinally potent chemicals predominantly belonging to polyphenols and sulphated polysaccharides. The chemicals have displayed an array of pharmacological properties especially antioxidant, immunostimulatory, and antitumour activities. The phytochemicals possibly activate macrophages, induce apoptosis, and prevent oxidative damage of DNA, thereby controlling carcinogenesis. In spite of vast resources enriched with chemicals, the marine floras are largely unexplored for anticancer lead compounds. Hence, this paper reviews the works so far conducted on this aspect with a view to provide a baseline information for promoting the marine flora-based anticancer research in the present context of increasing cancer incidence, deprived of the cheaper, safer, and potent medicines to challenge the dreadful human disease.

APA, Harvard, Vancouver, ISO, and other styles

24

Concepcion, Gisela, Marvin Altamia, Miguel Enrique Azcuna, April Cabang, Noel Lacerna II, Jose Miguel Robes, and Jortan Tun. "The Marine Environment: An Uncharted Resource for Drugs." Transactions of the National Academy of Science and Technology 39, no. 2017 (November 2021): 1–17. http://dx.doi.org/10.57043/transnastphl.2017.1069.

Full text

Abstract:

There is a strong “eco-bio-chemo-diversity” rationale to search the marine environment with its unique abiotic and biotic habitats for potential drug leads for serious pathological conditions such as cancer, infectious diseases, neurodegeneration and pain. Compounds produced by marine invertebrate organisms and their associated microorganisms that thrive successfully in five unique types of marine ecosystems are presented here as promising candidates for drug development. Marine organisms have evolved these chemicals to mediate specific biological and ecological interactions for their growth, development, defense and survival.

APA, Harvard, Vancouver, ISO, and other styles

25

Sruthi, Vadlakonda, Nagur Sharone Grace, Monica N., and Valishetti Manoj Kumar. "Marine pharmacology: an ocean to explore novel drugs." International Journal of Basic & Clinical Pharmacology 9, no. 5 (April 23, 2020): 822. http://dx.doi.org/10.18203/2319-2003.ijbcp20201767.

Full text

Abstract:

The rise in burden of diseases and treatment failure demands discovery of novel compounds. Exploiting natural sources which include territory of land and water in potential manner paves the way for significant future innovations in drug discovery. Marine environment has striking functionalities in its skeleton that has fascinated scientists to show enormous interest in investigation of new compounds. Marine sponges, algae, tunicates, sea whip etc. from the marine pipeline are the important sources for biological active compounds. Recent technology advancements further added to the domain of drug research in isolation and evaluation of marine derived products. To date, significant number of compounds have been isolated. Wide range of antibacterial, anti-inflammatory, antiparasitic, neuroprotective, antiviral, anticancer, analgesic, antimicrobial, antimalarial compounds have been pursued in control and management of diseases. These represent marine ecosystem as a hopeful resource in discovery of novel compounds with ideal starting point in scaffolding additional screening of natural marine products. This is review of abstracting on history, lead development process in identifying and comprehending basic nature of compounds that is promising initial step towards unique pharmacological design, the triumph of approved and ongoing trails, brief depiction on current status and challenges being faced in marine drug discovery field.

APA, Harvard, Vancouver, ISO, and other styles

26

Khalifa, Shaden A. M., Nizar Elias, Mohamed A. Farag, Lei Chen, Aamer Saeed, Mohamed-Elamir F. Hegazy, Moustafa S. Moustafa, et al. "Marine Natural Products: A Source of Novel Anticancer Drugs." Marine Drugs 17, no. 9 (August 23, 2019): 491. http://dx.doi.org/10.3390/md17090491.

Full text

Abstract:

Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new drugs with novel modes of action and thus considerable research has been conducted for new anticancer drugs from natural sources, especially plants, microbes and marine organisms. Marine populations represent reservoirs of novel bioactive metabolites with diverse groups of chemical structures. This review highlights the impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals. Anti-cancer effects of marine natural products in in vitro and in vivo studies were first introduced; their activity in the prevention of tumor formation and the related compound-induced apoptosis and cytotoxicities were tackled. The possible molecular mechanisms behind the biological effects are also presented. The review highlights the diversity of marine organisms, novel chemical structures, and chemical property space. Finally, therapeutic strategies and the present use of marine-derived components, its future direction and limitations are discussed.

APA, Harvard, Vancouver, ISO, and other styles

27

Jain, R. "Marine life: New hope for cancer drugs." Indian Journal of Cancer 46, no. 3 (2009): 243. http://dx.doi.org/10.4103/0019-509x.52963.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

S. Rangnekar, Sarvesh, and Tabassum Khan. "Novel Anti-inflammatory Drugs from Marine Microbes." Natural Products Journal 5, no. 3 (October 16, 2015): 206–18. http://dx.doi.org/10.2174/2210315505666150827212323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bhatnagar, Ira, and Se-Kwon Kim. "Marine Antitumor Drugs: Status, Shortfalls and Strategies." Marine Drugs 8, no. 10 (October 15, 2010): 2702–20. http://dx.doi.org/10.3390/md8102702.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Klausner, Arthur. "U.S. to Screen Marine Organisms for Drugs." Nature Biotechnology 4, no. 8 (August 1986): 684. http://dx.doi.org/10.1038/nbt0886-684a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Arizza, Vincenzo. "Marine biodiversity as source of new drugs." Italian Journal of Zoology 80, no. 3 (September 2013): 317–18. http://dx.doi.org/10.1080/11250003.2013.830370.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Dwivedi, Rohini, and Vitor H. Pomin. "Marine Antithrombotics." Marine Drugs 18, no. 10 (October 13, 2020): 514. http://dx.doi.org/10.3390/md18100514.

Full text

Abstract:

Thrombosis remains a prime reason of mortality worldwide. With the available antithrombotic drugs, bleeding remains the major downside of current treatments. This raises a clinical concern for all patients undergoing antithrombotic therapy. Novel antithrombotics from marine sources offer a promising therapeutic alternative to this pathology. However, for any potential new molecule to be introduced as a real alternative to existing drugs, the exhibition of comparable anticoagulant potential with minimal off-target effects must be achieved. The relevance of marine antithrombotics, particularly sulfated polysaccharides, is largely due to their unique mechanisms of action and lack of bleeding. There have been many investigations in the field and, in recent years, results have confirmed the role of potential marine molecules as alternative antithrombotics. Nonetheless, further clinical studies are required. This review covers the core of the data available so far regarding the science of marine molecules with potential medical applications to treat thrombosis. After a general discussion about the major biochemical steps involved in this pathology, we discuss the key structural and biomedical aspects of marine molecules of both low and high molecular weight endowed with antithrombotic/anticoagulant properties.

APA, Harvard, Vancouver, ISO, and other styles

33

Blunt, John W., Anthony R. Carroll, Brent R. Copp, Rohan A. Davis, Robert A. Keyzers, and Michèle R. Prinsep. "Marine natural products." Natural Product Reports 35, no. 1 (2018): 8–53. http://dx.doi.org/10.1039/c7np00052a.

Full text

Abstract:

This review of 2016 literature describes the structures and biological activities of 1277 new marine natural products and the structure revision and absolute configuration of previously reported MNPs. The chemical diversity of 28 609 MNPs reported since 1957 is also investigated and compared to that of approved drugs.

APA, Harvard, Vancouver, ISO, and other styles

34

Bhatia, Saurabh, Rashita Makkar, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Mahesh Rachamalla, Vasudevan Mani, Muhammad Shahid Iqbal, and Simona Gabriela Bungau. "Biotechnological Innovations from Ocean: Transpiring Role of Marine Drugs in Management of Chronic Disorders." Molecules 27, no. 5 (February 24, 2022): 1539. http://dx.doi.org/10.3390/molecules27051539.

Full text

Abstract:

Marine drugs are abundant in number, comprise of a diverse range of structures with corresponding mechanisms of action, and hold promise for the discovery of new and better treatment approaches for the management of several chronic diseases. There are huge reserves of natural marine biological compounds, as 70 percent of the Earth is covered with oceans, indicating a diversity of chemical entities on the planet. The marine ecosystems are a rich source of bioactive products and have been explored for lead drug molecules that have proven to be novel therapeutic targets. Over the last 70 years, many structurally diverse drug products and their secondary metabolites have been isolated from marine sources. The drugs obtained from marine sources have displayed an exceptional potential in the management of a wide array of diseases, ranging from acute to chronic conditions. A beneficial role of marine drugs in human health has been recently proposed. The current review highlights various marine drugs and their compounds and role in the management of chronic diseases such as cancer, diabetes, neurodegenerative diseases, and cardiovascular disorders, which has led to the development of new drug treatment approaches.

APA, Harvard, Vancouver, ISO, and other styles

35

Jeong, Geum-Jae, Sohail Khan, Nazia Tabassum, Fazlurrahman Khan, and Young-Mog Kim. "Marine-Bioinspired Nanoparticles as Potential Drugs for Multiple Biological Roles." Marine Drugs 20, no. 8 (August 18, 2022): 527. http://dx.doi.org/10.3390/md20080527.

Full text

Abstract:

The increased interest in nanomedicine and its applicability for a wide range of biological functions demands the search for raw materials to create nanomaterials. Recent trends have focused on the use of green chemistry to synthesize metal and metal-oxide nanoparticles. Bioactive chemicals have been found in a variety of marine organisms, including invertebrates, marine mammals, fish, algae, plankton, fungi, and bacteria. These marine-derived active chemicals have been widely used for various biological properties. Marine-derived materials, either whole extracts or pure components, are employed in the synthesis of nanoparticles due to their ease of availability, low cost of production, biocompatibility, and low cytotoxicity toward eukaryotic cells. These marine-derived nanomaterials have been employed to treat infectious diseases caused by bacteria, fungi, and viruses as well as treat non-infectious diseases, such as tumors, cancer, inflammatory responses, and diabetes, and support wound healing. Furthermore, several polymeric materials derived from the marine, such as chitosan and alginate, are exploited as nanocarriers in drug delivery. Moreover, a variety of pure bioactive compounds have been loaded onto polymeric nanocarriers and employed to treat infectious and non-infectious diseases. The current review is focused on a thorough overview of nanoparticle synthesis and its biological applications made from their entire extracts or pure chemicals derived from marine sources.

APA, Harvard, Vancouver, ISO, and other styles

36

Wu, Lichuan, Ke Ye, Sheng Jiang, and Guangbiao Zhou. "Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms." Marine Drugs 19, no. 9 (August 27, 2021): 488. http://dx.doi.org/10.3390/md19090488.

Full text

Abstract:

Worldwide, 19.3 million new cancer cases and almost 10.0 million cancer deaths occur each year. Recently, much attention has been paid to the ocean, the largest biosphere of the earth that harbors a great many different organisms and natural products, to identify novel drugs and drug candidates to fight against malignant neoplasms. The marine compounds show potent anticancer activity in vitro and in vivo, and relatively few drugs have been approved by the U.S. Food and Drug Administration for the treatment of metastatic malignant lymphoma, breast cancer, or Hodgkin′s disease. This review provides a summary of the anticancer effects and mechanisms of action of selected marine compounds, including cytarabine, eribulin, marizomib, plitidepsin, trabectedin, zalypsis, adcetris, and OKI-179. The future development of anticancer marine drugs requires innovative biochemical biology approaches and introduction of novel therapeutic targets, as well as efficient isolation and synthesis of marine-derived natural compounds and derivatives.

APA, Harvard, Vancouver, ISO, and other styles

37

Dyshlovoy, Sergey A., and Friedemann Honecker. "Marine Compounds and Cancer: Updates 2022." Marine Drugs 20, no. 12 (December 1, 2022): 759. http://dx.doi.org/10.3390/md20120759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Der Marderosian, Ara. "Biodynamic Agents from Marine Sources as Potential Drugs." Marine Technology Society Journal 40, no. 2 (May 1, 2006): 58–64. http://dx.doi.org/10.4031/002533206787353547.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Laport, M., O. Santos, and G. Muricy. "Marine Sponges: Potential Sources of New Antimicrobial Drugs." Current Pharmaceutical Biotechnology 10, no. 1 (January 1, 2009): 86–105. http://dx.doi.org/10.2174/138920109787048625.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ravi, Akshara, M. Gokul Raj, Sathiavelu Arunachalam, and Mythili Sathiavelu. "Marine environment: A potential source for anticancer drugs." Research Journal of Pharmacy and Technology 10, no. 5 (2017): 1543. http://dx.doi.org/10.5958/0974-360x.2017.00272.4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Muralidharan, V., and M. Deecaraman. "A Source of Novel Therapeutic Drugs-Marine Actinomycetes." Research Journal of Pharmacy and Technology 10, no. 10 (2017): 3598. http://dx.doi.org/10.5958/0974-360x.2017.00652.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Chakraborty, Chiranjib, Chi-Hsin Hsu, Zhi-Hong Wen, and Chan-Shing Lin. "Anticancer Drugs Discovery and Development from Marine Organisms." Current Topics in Medicinal Chemistry 9, no. 16 (November 1, 2009): 1536–45. http://dx.doi.org/10.2174/156802609789909803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Marine Drugs Editorial Office. "Acknowledgement to Reviewers of Marine Drugs in 2013." Marine Drugs 12, no. 2 (February 24, 2014): 1160–68. http://dx.doi.org/10.3390/md12021160.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Marine Drugs Editorial Office. "Acknowledgement to Reviewers of Marine Drugs in 2014." Marine Drugs 13, no. 1 (January 7, 2015): 267–75. http://dx.doi.org/10.3390/md13010267.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Russo, Patrizia, Aliaksei Kisialiou, Palma Lamonaca, Rossana Moroni, Giulia Prinzi, and Massimo Fini. "New Drugs from Marine Organisms in Alzheimer’s Disease." Marine Drugs 14, no. 1 (December 25, 2015): 5. http://dx.doi.org/10.3390/md14010005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Montaser, Rana, and Hendrik Luesch. "Marine natural products: a new wave of drugs?" Future Medicinal Chemistry 3, no. 12 (September 2011): 1475–89. http://dx.doi.org/10.4155/fmc.11.118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Silvestre, Francesco, and Elisabetta Tosti. "Impact of Marine Drugs on Animal Reproductive Processes." Marine Drugs 7, no. 4 (November 6, 2009): 539–64. http://dx.doi.org/10.3390/md7040539.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Thomas, Tresa Remya A., Devanand P. Kavlekar, and Ponnapakkam A. LokaBharathi. "Marine Drugs from Sponge-Microbe Association—A Review." Marine Drugs 8, no. 4 (April 22, 2010): 1417–68. http://dx.doi.org/10.3390/md8041417.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Sato, Aiya. "The Search for New Drugs from Marine Organisms." Journal of Toxicology: Toxin Reviews 15, no. 2 (January 1996): 171–98. http://dx.doi.org/10.3109/15569549609064083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Jimenez, Paula C., Diego V. Wilke, Paola C. Branco, Anelize Bauermeister, Paula Rezende‐Teixeira, Susana P. Gaudêncio, and Leticia V. Costa‐Lotufo. "Enriching cancer pharmacology with drugs of marine origin." British Journal of Pharmacology 177, no. 1 (December 23, 2019): 3–27. http://dx.doi.org/10.1111/bph.14876.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!